Electronic cigarettes pose less danger than traditional smoking

Jul.08.2022
Electronic cigarettes pose less danger than traditional smoking
Evidence shows that vaping is less harmful than smoking and can help smokers quit, but media coverage has hindered public understanding.

The evidence is clear: vaping is less dangerous than smoking and can help many people quit their deadly smoking habit. No public data can refute these two conclusions, but tobacco control researchers, activists, and federal regulatory agencies often deny or downplay these observations. This contaminates the public's understanding of electronic cigarettes and prevents smokers from trying out alternative solutions that could potentially save their lives.


Using electronic cigarettes helped me successfully quit smoking, according to a recent conclusion published in the American Journal of Preventive Medicine. Medscape reported on June 20 that "an increasing number of American adults believe that electronic cigarettes are more harmful than traditional cigarettes.


Why are the public afraid of electronic cigarettes?


The author analyzed data collected as part of the Health Information National Trends Survey (HINTS), which is a nationally representative survey conducted through mail that asks American adults about their attitudes towards cancer and other health-related information. The data was collected over five cycles between January 2018 and May 2020, with over 3000 respondents included in the final analysis each year (3360 in 2018, 3217 in 2019, and 3677 in 2020). The author reports that...


The relative perceived harm of electronic cigarettes versus traditional cigarettes was assessed through the following question with six possible answers: Compared to smoking, would you say that electronic cigarettes are... Respondents were categorized as perceiving electronic cigarettes to be less harmful (less harmful or much less harmful) than traditional cigarettes, equally harmful, or more harmful (more harmful or much more harmful) than traditional cigarettes.


The author suggests that the negative shift in perception may have been driven by the media's coverage of the so-called "EVALI outbreak". From 2019 to 2020, over 2,000 individuals were hospitalized due to e-cigarette related lung injuries and 68 people died.


These cases were not caused by electronic cigarettes themselves, which were mistakenly maintained by the Centers for Disease Control and Prevention for a few months, but by devices purchased illegally for vaping THC or CBD. These chemicals, derived from cannabis rather than tobacco, were mixed with vitamin E acetate which may have contributed to the reported lung injuries. Dr. Josh Bloom provided a helpful explanation of the chemical reaction behind this phenomenon in the story, which subsequent research has confirmed.


During the outbreak of EVALI, journalists did what they often do without having all the facts: they amplified the risk, with the tacit approval of the Centers for Disease Control, but were not interested in reporting on the controversy surrounding the decision. According to the study authors:


In March and April of 2020, there was a high level of harmful relative opinions. This suggests that misunderstandings have persisted since the initial discovery of the connection to vitamin E acetate in September 2019, possibly due to media coverage not remaining at the same level after the source of the epidemic was determined.


The trend is still continuing.


EVALI is no longer a major public health concern, but controversial ideological radicalism and careless reporting continue to undermine electronic cigarettes as a harm reduction tool in today's society. Researchers have published low-quality studies alleging serious health consequences from using e-cigarettes, and the media dutifully reported on these findings. The ACSH and other scientifically-minded media outlets have corrected the propaganda, but unfortunately, this good news has not garnered as much attention as sensational and scary headlines.


Experts recognize the issue and acknowledge the need for a solution. According to a doctor, we are effective at communicating the harmful effects of smoking and the dangers of tobacco in public health. Ashley Brooks-Russell, associate professor at the Colorado School of Public Health, stated to Medscape Medical News that we struggle to discuss smaller choices, such as the lesser harm of e-cigarettes compared to smoking.


Dr. Russell is correct, but I will go even further. Even though researchers have documented the harm caused by common anti-vaping metaphors, tobacco researchers cannot abandon their skepticism of e-cigarettes. As the authors of the study themselves have written,


Electronic cigarettes contain high levels of nicotine and appealing flavors that may lead to addiction and the use of combustible tobacco products among adolescents and young adults.


The sentence is at least partially false. Many electronic cigarettes contain little to no nicotine. Flavored electronic cigarettes do not encourage youth to use any tobacco products, and there is no concrete evidence to support this speculation. The author also reiterated the anti-electronic cigarette stance, which has become a staunch article among tobacco researchers: "The risks associated with long-term use are still unclear." This is undoubtedly true, as no one has a crystal ball, but public health researchers often use such language to suggest that we will discover some serious risks associated with electronic cigarettes in the future.


The American Cancer Society claims that the long-term risks of only using electronic cigarettes are not yet fully clear. However, there is increasing evidence that using e-cigarettes has negative effects on the cardiovascular system and lungs. If immediate action is not taken to stop the widespread use of these products, the long-term adverse health effects will increase.


Can you imagine a large medical institution issuing a statement similar to this regarding the use of COVID-19 vaccines or puberty blockers for treating gender dysphoria? After all, we do not know the potential long-term effects of these powerful drugs on those who take them. Of course, until we have a better understanding of these products, we must halt their "popular use," shouldn't we?


If these issues are frustrating you, then maybe you're starting to understand why the popular rhetoric surrounding e-cigarettes is so absurd. Properly evaluating any product requires accurately balancing its risks and benefits. No one is claiming that e-cigarettes are risk-free; they are an effective intervention aimed at reducing the harm of smoking, which is killing people all over the world.


Given this standard, speculating about potential hazards we may discover one day is a foolish thought exercise. Let the public know what we know today: for adult smokers who want to quit smoking, electronic cigarettes are a low-risk option.


This article is compiled from third-party information and is only intended for educational purposes. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
UK Vape Tax Reshapes Costs: VPZ's £1.5 Million Plan, Totally Wicked's Three HMRC Approvals and VSL's Wholesale Challenge
UK Vape Tax Reshapes Costs: VPZ's £1.5 Million Plan, Totally Wicked's Three HMRC Approvals and VSL's Wholesale Challenge
Britain's new vaping excise duty, introduced on October 1, 2026, is changing how manufacturers, distributors and retailers manage production, inventory and tax compliance. Specialist vape retailer VPZ reportedly plans to invest up to £1.5 million in production and duty-stamp systems, following earlier plans for a fifth production line, bonded warehousing and 40 additional stores. Rival Totally Wicked says it has obtained three HMRC approvals covering manufacturing, duty-suspended storage and representation of overseas manufacturers. Wholesale distributor Vape Supplier Limited (VSL) has identified stock conversion costs, warehousing requirements and margin pressure among its business risks. The companies illustrate how different operating models are responding to Britain's new tax and product-traceability requirements.
Market
Nov.16
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Japan Tobacco Inc. (JT) confirmed on November 9, 2026, that all seven of its Russian entities had been placed under temporary administration after a second presidential decree added three companies to the four designated a day earlier. The additional entities are associated with importing, management, holdings and the former supply of Ploom heated-tobacco devices. JT disclosed approximately ¥1.5 trillion in Russian business-related assets as of September 30, including ¥360 billion in cash and deposits, and approximately ¥200 billion in liabilities. Under its revised FY2026 forecast, Russia accounts for about 25% of adjusted operating profit. JT said operations in Russia were continuing, while the financial impact remained under assessment.
company
Nov.09
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23